Neuro-Oncology Advances : Impact Factor & More
eISSN: 2632-2498
Open AccessShare this on:
Key Metrics
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Neuro-Oncology Advances
Neuro-Oncology Advances Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Oxford University Press |
| Language | English |
| Article Processing Charges | GBP 1500 | USD 2206 |
| Publication Time | 12 |
| Editorial Review Process | Peer review |
| General Details | |
| Publication Details | |
| Publication Time | 12 |
| Waiver Policy | Visit website |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Neuro-Oncology Advances ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Neuro-Oncology Advances
The neurobiology of survivorship: Cognitive consequences of modern oncology
- 22 Jun 2026
- Neuro-Oncology Advances
Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab
- 9 Jun 2026
- Neuro-Oncology Advances
Sensitivity and specificity of cerebrospinal fluid placental alkaline phosphatase in germinoma: An 8 pg/mL threshold
- 5 Jun 2026
- Neuro-Oncology Advances
A new method for optimal placement of tumor treating fields electrodes
- 3 Jun 2026
- Neuro-Oncology Advances
Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis
- 2 Jun 2026
- Neuro-Oncology Advances
Pharmacologic inhibition of RBBP4/p300-mediated homologous recombination activity enhances glioblastoma sensitivity to temozolomide
- 29 May 2026
- Neuro-Oncology Advances
The neurobiology of survivorship: Cognitive consequences of modern oncology
- 22 Jun 2026
- Neuro-Oncology Advances
Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab
- 9 Jun 2026
- Neuro-Oncology Advances
Sensitivity and specificity of cerebrospinal fluid placental alkaline phosphatase in germinoma: An 8 pg/mL threshold
- 5 Jun 2026
- Neuro-Oncology Advances
A new method for optimal placement of tumor treating fields electrodes
- 3 Jun 2026
- Neuro-Oncology Advances
Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis
- 2 Jun 2026
- Neuro-Oncology Advances
Pharmacologic inhibition of RBBP4/p300-mediated homologous recombination activity enhances glioblastoma sensitivity to temozolomide
- 29 May 2026
- Neuro-Oncology Advances
FAQs on Neuro-Oncology Advances
How many articles did Neuro-Oncology Advances publish last year? 
Who is the publisher of Neuro-Oncology Advances?
